FDA Approves High-Dose Wegovy 7.2mg for Obesity in 2026
The FDA approved high-dose semaglutide 7.2mg (Wegovy) for obesity, showing 18.7% mean weight loss in Phase 3 trials amid new Trump administration drug pricing agreements.
By Sarah Tanaka
Wegovy
2 articles tagged "Wegovy"
Wegovy Linked to Higher Ischemic Optic Neuropathy Risk
New FAERS analysis finds Wegovy carries nearly fivefold higher ischemic optic neuropathy risk vs. Ozempic, raising ocular safety concerns for GLP-1 drugs.
By Sarah Tanaka